Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cerner Corp.

www.cerner.com

Latest From Advanced Inhalation Research Inc.

A Really Near-Term Application for Discovery Technology: Momenta and Sandoz Attempt a Biogeneric

The press release was foggy; Sandoz Inc., the generics unit of Novartis AG, was teaming up with a biotech, Momenta Pharmaceuticals Inc. to commercialize "complex pharmaceutical products." Upon closer examination, the deal in fact has wide-ranging implications, representing the very real near-term possibility of a true generic biologic,
BioPharmaceutical

Inhalable Drug Delivery

Over the past few years, the drug delivery industry has seen a major change in its basic structure. Nowhere is this more true than in the subsegment of inhalable drug delivery. One of the big drivers of the change: drug delivery companies angling for market share in partnering.
BioPharmaceutical Business Strategies

Alkermes' Incrementalism

Alkermes' success in creating a commercial product out of Genentech's growth hormone has taken it across a fundamental credibility gap all new drug delivery companies face. One result: an extraordinarily high valuation that has permitted it to raise plenty of cash. And it's using these assets--credibility, cash and valuation--to invest in programs which can bring it nearer term revenues and higher margins, in terms of new, accelerated, or risk-sharing deals. Indeed, it's even treating its current net-loss position as an asset, spending heavily now--which its profitable competitors can't, given their valuation-sensitive earnings constraints--and even signing complex deals to take its partners' expenses onto its own P&L, reimbursing itself with equity and downstream milestones. Moreover, it's shown itself, as in its acquisition of Advanced Inhalation Research, willing to dramatically expand its portfolio of technologies with work done on the outside. Alkermes also wants to develop products for its own account, though its strategy for commercializing them, while maintaining a strong delivery technology base, is unclear.
BioPharmaceutical Business Strategies

Drug Delivery Start-Ups

As an industry segment, drug delivery was virtually created by two companies--Alza Corp. and Elan Corp. PLC. These companies have since evolved into drug companies, abandoning a significant part of the field to second-generation arrivistes. Such companies that have survived the funding drought for small-cap companies have benefited, Inhale Therapeutics, for example, has a number of partnerships for its pulmonary delivery technology. Alkermes, probably the leading drug-delivery pure play, now has its first approved product. What is somewhat surprising about the industry is how little it has consolidated, particularly when one considers that no single drug delivery technology is applicable to a majority of drug delivery problems.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Pacs (Picture Archive & Communications Systems)
    • Monitoring Equipment & Devices
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cerner Corp.
  • Senior Management
  • Neal L Patterson, Chmn. & CEO
    Marc G Naughton, EVP, CFO
    Cliff Illig, Vice Chairman
    Zane Burke, President
    Mike Nill, EVP & COO
    Jeff Townsend, EVP and Chief of Staff
  • Contact Info
  • Cerner Corp.
    Phone: (816) 221-1024
    2800 Rockcreek Pkwy
    North Kansas City, MO 64117-2551
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register